Click here to register for the upcoming CAA Webinar: Nov. 23, 2024 at 12:00PM

Presented via Zoom by the International CAA Association & Amyloidosis Support Group

Interested in CAA Research?

Want to know more about the CAA treatment trial: cAPPricorn-1?

Welcome to the website for the Cerebral Amyloid Angiopathy Research Program at Massachusetts General Hospital. This website is intended as a resource for patients and families living with CAA and the investigators and clinicians who work in this field.

**Steven M. Greenberg MD, PhD** is Director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital, and Professor of Neurology at Harvard Medical School.

Initiated in 1994, the Hemorrhagic Stroke Research Program at Massachusetts General Hospital has become internationally recognized as a leading authority on the causes, diagnosis, and treatment of cerebral amyloid angiopathy.

Cerebral amyloid angiopathy (CAA) refers to protein deposits in blood vessels of the brain that can allow blood to leak out and cause hemorrhagic (bleeding) strokes in the elderly. At the molecular level, it is also closely related to Alzheimer's disease (AD) through the protein amyloid beta-peptide. There are currently no effective prevention or treatment strategies for CAA.

Our goal is to understand the causes of CAA, and identify safe and effective treatments for lowering the risk of recurrent hemorrhage, and other forms of clinical deterioration in patients with CAA.

By collaborating with other physician-scientists studying the role of amyloid beta-peptide (a major factor in CAA) in Alzheimer's disease, we can leverage their expertise in multiphoton imaging techniques, and have opportunities to exchange insights that may lead to a better understanding of both.

Our research is divided into a clinical program that focuses on the molecular epidemiology of CAA, and a laboratory program studying its pathogenesis.